H22 Syngeneic Model Service for Liver Cancer

The H22 syngeneic model is the most published immunocompetent platform for hepatocellular carcinoma research, engrafting a murine hepatoma line — maintained for decades as an ascites tumor before solid and orthotopic formats were standardized — into BALB/c hosts with rapid, reproducible growth and documented checkpoint responsiveness. Alfa Cytology delivers this workhorse model as a complete preclinical service — authenticated cell banking with the line's ascites-passage tradition, subcutaneous, intraperitoneal ascites, and orthotopic left-lobe liver implantation formats, scheduled monitoring, and full histopathology — giving sponsors a fast, flexible HCC system without managing strain-matched husbandry and hepatic microsurgery in-house.

Overview of H22 Syngeneic Model for Liver Cancer

H22 is arguably the most extensively used murine hepatoma line in the world, and its biography explains why: it was derived from the ascites of a mouse bearing hepatocellular carcinoma and propagated for generations as an ascites tumor — intraperitoneal passage from mouse to mouse, with tumor cells harvested from the peritoneal fluid — before laboratories standardized solid flank tumors and orthotopic liver implants. That ascites lineage gives the line an unusual personality: it grows in suspension with lymphoblast-like morphology, proliferates explosively (a 25-fold expansion in a week documented for a derived subline), secretes hepatocyte growth factor, and forms tumors through virtually every route — subcutaneous, intraperitoneal, intravenous, portal vein, and direct hepatic implantation. The standard syngeneic host is BALB/c, in which subcutaneous inoculation of 10⁶ cells in 50 μL produces palpable tumors within 4–6 days at take rates above 95%, with in vivo doubling on the order of 3–4 days. Orthotopically, 5 × 10⁵ cells implanted into the left liver lobe recreate the hepatic microenvironment — and the orthotopic setting measurably reshapes the immune landscape, expanding regulatory T cells and myeloid-derived suppressor cells in tumor, spleen, and bone marrow just as human HCC does.

Fig 1. Characterization of the half-life-extended anti-CTLA-4 VHH validated in the H22 syngeneic hepatoma model — H11 and H11-HLE construct design, binding to mouse CTLA-4 (EC50 0.048 nM and 0.064 nM), and plasma/tumor pharmacokinetics showing H11-HLE achieves 53 h plasma and 79 h tumor half-life versus 2.6 h and 4.5 h for H11, underpinning its anti-tumor efficacy in H22 tumor-bearing BALB/c mice. (Sato, Yosuke, et al., 2020)

The model's publication record spans virtually every drug class tested against liver cancer. Checkpoint blockade is validated — anti-PD-1 at 5 mg/kg weekly for three doses is a published reference regimen in the flank model — and a landmark Science Translational Medicine study used the H22 orthotopic platform to show that the HDAC8 inhibitor PCI-34051 potentiates anti-PD-L1 therapy, with combination-treated animals surviving beyond fifteen months and resisting rechallenge. H22 has carried oncolytic herpes virotherapy delivered intravenously against orthotopic disease, sorafenib-derivative evaluation, AFP-cDNA dendritic-cell vaccination, microRNA mechanism studies, hepatic stellate cell co-implantation experiments that expose how activated stellate cells drive angiogenesis and immune suppression, and portal-vein injection models of metastatic spread. Two niche roles deserve note: the line is the default vehicle for hepatoprotective and natural-product pharmacology in the Chinese literature, and the derived H22-F25/L subline — selected through a lymphatic metastasis model — forms tumors in 615 mice with 50% lymph node and 10% lung metastasis rates, extending the family's metastatic utility. Luciferase-tagged H22-Luc and H22-Luc-GFP derivatives enable quantitative bioluminescence tracking of flank and orthotopic disease, and one honest caution from the recent literature: H22 is BALB/c-lineage, so studies run in C57BL/6 hosts risk allogeneic confounding — a design question Alfa Cytology addresses by defaulting to BALB/c unless a program explicitly requires otherwise.

Cell Line Information: H22

H22 (Hepatoma-22; Cellosaurus CVCL_H613; Cytion 305163; National Infrastructure of Cell Line Resource, Beijing) is a murine hepatocellular carcinoma line with an ascites-tumor lineage, distributed by Chinese national repositories and international cell banks. Luciferase- and fluorescent-protein-tagged derivatives (H22-Luc; H22-Luc-GFP-Puro, lentiviral, puromycin-selected) support optical tracking studies. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the H22 syngeneic model consolidates a complete, IACUC-compliant program under one accountable team: authenticated, low-passage H22 banks are maintained — honoring the line's ascites-passage tradition and suspension-culture discipline — BALB/c hosts are sourced from validated breeders and acclimated, tumors are established by subcutaneous, intraperitoneal ascites, or orthotopic left-lobe liver routes at documented take rates, and treatment arms from checkpoint inhibitors to natural-product formulations and oncolytic vectors run through scheduled caliper and bioluminescence monitoring to terminal hepatic and pulmonary histopathology, all returned as an audit-ready data package.

Workflow of H22 Syngeneic Model Construction

H22 studies offer three formats — flank, ascites, and orthotopic liver — united by the line's suspension-culture discipline and BALB/c strain fidelity. A standard program proceeds as follows.

1. Cell preparation and quality control: H22 cells (or H22-Luc derivatives) are expanded in suspension culture, confirmed mycoplasma-free with bacterial, fungal, and Helicobacter screening where the ascites tradition demands, and luciferase activity validated in vitro; inocula are prepared fresh at defined concentrations.
2. Host selection and acclimation: Female BALB/c mice, typically 6–8 weeks of age, are sourced from validated breeders, quarantined, and acclimated in a specific-pathogen-free barrier facility, with C57BL/6 substitution avoided given the documented allogeneic confound.
3. Implantation: subcutaneous route. 10⁶ cells in 50 μL sterile PBS are injected into the flank; the site is compressed briefly on needle withdrawal, and palpable tumors typically appear within 4–6 days.
4. Implantation: ascites route. Cells in 0.2 mL saline (classically 1 × 10⁷ cells/mL) are injected intraperitoneally; on the standard 7-day cycle, ascites is harvested aseptically for passage, counts, or direct study of malignant effusion biology.
5. Implantation: orthotopic liver route. Under isoflurane anesthesia, a left subcostal laparotomy exposes the left lateral lobe, and 5 × 10⁵ cells in 20 μL PBS are injected into the hepatic parenchyma with a fine needle; the lobe is returned and the abdomen closed in layers.
6. Randomization and treatment: Mice are randomized at a defined tumor volume (for example day 7 for flank tumors) or post-implantation interval for orthotopic cohorts, and test articles — checkpoint inhibitors, oncolytic viruses, targeted agents, or natural-product formulations — are dosed per protocol with body weight and clinical signs recorded.
7. Longitudinal monitoring: Flank tumors are measured by caliper every 2–3 days (volume = length × width² / 2); luciferase-tagged cohorts undergo bioluminescence imaging after intraperitoneal D-luciferin injection, and orthotopic studies track survival against 100-day monitoring windows.
8. Endpoint analysis and reporting: At termination, tumors and livers are resected and weighed; tissues undergo H&E with hepatic histology, immunohistochemistry (CD8, FoxP3, F4/80, CD31, PD-L1 panels), flow-cytometric tumor-infiltrating-leukocyte and bone-marrow/splenic immune profiling where specified, and metastatic organ screening, with all data consolidated into the final report.

Fig 2. H22 Syngeneic Model construction workflow.

Case Study-H22 Syngeneic Model Development

Alfa Cytology has applied the H22 syngeneic platform to preclinical programs spanning checkpoint inhibitor evaluation, HDAC-inhibitor combinations, oncolytic virotherapy, targeted and natural-product pharmacology, and hepatic microenvironment studies in liver cancer. In these engagements, caliper and bioluminescence readouts tracked flank and orthotopic tumor kinetics, while terminal hepatic histopathology with immune-marker panels and splenic and bone-marrow immune profiling completed the pharmacological and immunological assessment. Study parameters — implantation format, strain logistics, monitoring cadence, and endpoint panels — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

H22 is deceptively simple — until a study ignores its ascites lineage, its suspension-culture discipline, or its strain genetics, at which point results quietly lose meaning. Alfa Cytology fields these capabilities in-house, making the H22 / H22-Luc syngeneic model a dependable backbone for your liver cancer program.

• Ascites-lineage stewardship, honoring the line's intraperitoneal passage tradition and suspension culture requirements.
• Three validated formats — flank, malignant ascites, and orthotopic left-lobe liver — under one roof.
• BALB/c strain discipline, with the documented C57BL/6 allogeneic confound designed out by default.
• Checkpoint benchmark fluency, including the published anti-PD-1 reference regimen and HDAC8-combination precedent.
• Orthotopic immune-depth, tracking Treg and MDSC dynamics across tumor, spleen, and bone marrow.
• Hepatoprotective pharmacology experience, the line's signature niche in natural-product research.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your liver cancer program needs the world's most published murine hepatoma platform with the expertise to run it properly, contact us today to discuss H22 / H22-Luc study design, implantation format, and endpoint strategy with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.